{"Symbol": "ESPR", "AssetType": "Common Stock", "Name": "Esperion Therapeutics, Inc", "Description": "Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "3891 Ranchero Drive, Ann Arbor, MI, United States, 48108", "FullTimeEmployees": "193", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "903768960", "EBITDA": "-79313000", "PERatio": "None", "PEGRatio": "-4.78", "BookValue": "3.08", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-2.863", "RevenuePerShareTTM": "7.875", "ProfitMargin": "-0.3886", "OperatingMarginTTM": "-0.324", "ReturnOnAssetsTTM": "-0.1369", "ReturnOnEquityTTM": "-0.7817", "RevenueTTM": "216039008", "GrossProfitTTM": "-27247000", "DilutedEPSTTM": "-3.061", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "215.126", "AnalystTargetPrice": "87", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "4.3174", "PriceToBookRatio": "11.0665", "EVToRevenue": "3.0158", "EVToEBITDA": "0", "Beta": "1.9747", "52WeekHigh": "76.98", "52WeekLow": "24.82", "50DayMovingAverage": "39.0544", "200DayMovingAverage": "43.332", "SharesOutstanding": "27825400", "SharesFloat": "25386807", "SharesShort": "10127507", "SharesShortPriorMonth": "9367093", "ShortRatio": "14.86", "ShortPercentOutstanding": "0.4", "ShortPercentFloat": "0.4602", "PercentInsiders": "2.862", "PercentInstitutions": "101.109", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:6", "LastSplitDate": "2013-06-11"}